Expecto Health Science appoints Dr Pramod Kashid as its new CEO

New Delhi/Singapore: Expecto Health Science Pte Ltd, a scientifically driven full-service Contract Research Organization, CRO, founded in 2023 and headquartered in Singapore has announced the appointment of Dr Pramod Kashid as Chief Executive Officer, last week.

Dr. Pramod Kashid is a trailblazer in the world of clinical research, boasting over twenty illustrious years as a leader in Global Clinical Research Management. His journey began as a Clinical Research Associate at Sanofi Aventis, where he swiftly rose through the ranks.

Currently based in Singapore, Dr Kashid held the position of Executive Director, Clinical Trial Management at Medpace until recently. With his extensive knowledge and experience, he lent his guiding hand to a plethora of global clinical research projects across the dynamic Asia-Pacific region. His leadership prowess led to the successful establishment of clinical research operations in an impressive thirteen countries in the APAC region, revolutionizing the landscape of company expansion in new markets.

Sharing his comments with BioVoice News, Dr Pramod Kashid said: “As I step into my role at Expecto Health Science, I am both humbled and excited to make Expecto Health Science a leading CRO in the Asia Pacific region. Expecto Health Science is uniquely positioned to capitalize on the burgeoning clinical research opportunities within the Asia-Pacific region. My mission which aligns with the company’s, is to provide early access of new therapies to patients from emerging markets and at the same time, to reduce the cost of conducting clinical trials while maintaining quality and regulatory compliance.”

“We are committed to fostering strong partnerships with mid-size and small pharmaceutical companies, biotech firms, medical device innovators, and simultaneously, we aim to partner with local and global CROs. With the depth of experience within our leadership team and our relentless focus on quality, we are confident in our ability to not only meet but exceed the expectations of our clients and stakeholders,” added Dr Kashid.

Dr Kashid has a PhD in Pharmaceutical Sciences and a Master of Pharmacy from the esteemed SVKM’s Narsee Monjee Institute of Management Studies (NMIMS), Mumbai, and an MBA from Saïd Business School, University of Oxford.

Dr Kashid joins Expecto Health Science’s leadership team to drive clinical research innovations in emerging economies and make a significant regional impact with a global outlook.

Expecto Health Science, focuses on emerging economies in APAC and offers comprehensive and cost-effective clinical research services to manage Phase I to Phase IV global and regional clinical trials.